BioAtla (BCAB) EBIT Margin (2020 - 2026)

BioAtla's (BCAB) quarterly EBIT Margin came in at 3.49% in Q2 2026, up 100.75% quarter-over-quarter from 462.75% in Q4 2025.

Analysis

BioAtla (BCAB) EBIT Margin (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported EBIT Margin for 5 consecutive years, with 3.49% the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, EBIT Margin changed N/A year-over-year to 3.49%; the trailing twelve-month figure through Jun 2026 stood at 377.94% (up 20183.0% YoY), and the FY2025 full-year result was 2965.25%, down 229304.0% from the prior year.
EBIT Margin advanced to 3.49% in Q2 2026 per BCAB's latest filing, from 462.75% in the prior quarter.
Across five years, EBIT Margin topped out at 3.49% in Q2 2026 and bottomed at 462.75% in Q4 2025.
Historically, EBIT Margin has averaged 187.24% across 3 years, with a median of 102.45% in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	34.95%
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	30.15%
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	32.54%
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	17.93%
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	-23.56%
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	-0.36%
10	BioAtla	2.33 Mn	2.33 Mn	-	3.49%

Historic Data

Download Data